Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

2.61USD
4:00pm EDT
Change (% chg)

$0.03 (+1.16%)
Prev Close
$2.58
Open
$2.58
Day's High
$2.62
Day's Low
$2.54
Volume
196,796
Avg. Vol
309,328
52-wk High
$4.24
52-wk Low
$0.57

Latest Key Developments (Source: Significant Developments)

Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit
Tuesday, 26 Dec 2017 05:42pm EST 

Dec 26 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT.AVEO- UNDER MOU, AGREED FOR PLAINTIFFS TO CAUSE SOME OF CO'S, INDIVIDUAL DEFENDENTS' INSURANCE CARRIERS TO PROVIDE THE CLASS WITH $15 MILLION CASH PAYMENT.AVEO PHARMACEUTICALS SAYS ADDITIONALLY, CO AGREED TO ISSUE TO THE CLASS WARRANTS FOR PURCHASE OF 2 MILLION SHARES OF AVEO COMMON STOCK - SEC FILING.AVEO PHARMACEUTICALS - IN CONSIDERATION OF SETTLEMENT PAYMENT, PLAINTIFFS AGREED THAT SETTLEMENT WILL INCLUDE DISMISSAL OF CLASS ACTION WITH PREJUDICE.AVEO PHARMA - CONSIDERING SETTLEMENT PAYMENT, PLAINTIFFS AGREED SETTLEMENT WILL INCLUDE RELEASE OF ALL CLAIMS AGAINST CO, INDIVIDUAL DEFENDANTS BY THE CLASS.  Full Article

Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln
Thursday, 30 Nov 2017 05:39pm EST 

Nov 30 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Aveo Pharmaceuticals Inc :AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.22.‍BELIEVE THAT OUR $37.4 MILLION IN CASH RESOURCES WOULD ALLOW US TO FUND OUR PLANNED OPERATIONS INTO Q4 OF 2018​.  Full Article

Aveo Pharmaceuticals files for non-timely 10-K - SEC filing
Friday, 17 Mar 2017 04:30pm EDT 

Aveo Pharmaceuticals Inc : Files for non-timely 10-K - SEC filing . Says identified a material weakness in its internal control over financial reporting. . Aveo Pharmaceuticals - based on preliminary figures, expects to report net loss of $0.39 per basic and diluted share, for year ended December 31, 2016 .Aveo Pharmaceuticals - material weakness related to company's failure during 2016 to regularly reconcile U.K. bank account held by co's U.K. subsidiary.  Full Article

Aveo initiates evaluation of Tivozanib in combination with Bristol-Myers Squibb's opdivo in advanced renal cell carcinoma
Monday, 15 Aug 2016 07:00am EDT 

Aveo : Initiates Evaluation Of Tivozanib In Combination With Bristol Myers Squibb's Opdivo® (nivolumab) in advanced renal cell carcinoma .Phase 1/2 tinivo trial to commence at institut gustave roussy in paris.  Full Article

Aveo Oncology Q2 loss per share $0.13
Thursday, 4 Aug 2016 07:35am EDT 

Aveo Pharmaceuticals Inc : Aveo oncology reports second quarter 2016 financial results and provides business update . Q2 loss per share $0.13 Further company coverage: [AVEO.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Aveo Pharmaceuticals says sale of 37.1 mln shares by stockholders
Wednesday, 15 Jun 2016 05:12pm EDT 

Aveo Pharmaceuticals Inc :Announces sale of 37.1 million shares of common stock by selling stockholders - sec filing.  Full Article

Aveo Pharmaceuticals announces dosing of first patient in Phase 3 tivo-3 study of tivozanib in renal cell carcinoma
Thursday, 26 May 2016 07:00am EDT 

Aveo Pharmaceuticals Inc : Announces dosing of first patient in pivotal Phase 3 tivo 3 study of tivozanib in renal cell carcinoma .Top line readout of study is currently projected for Q1 of 2018.  Full Article

Aveo Pharmaceuticals announces closing of private placement and amended term loan
Wednesday, 18 May 2016 07:00am EDT 

Aveo Pharmaceuticals Inc : Announces closing of private placement and amended term loan to fund pivotal Tivo 3 trial and combination PD-1 trial of tivozanib in renal cell cancer . Entered into an amendment to its 2010 loan and security agreement with Hercules Capital Inc . Pursuant to loan amendment, company borrowed an additional $5.0 million from Hercules . If specified conditions are met, Aveo may borrow an additional tranche of $5.0 million from Hercules in first half of 2017 .If specified conditions are met, repayment of principal on Aveo's loans may be deferred to begin in 2018.  Full Article

Aveo says private placement to consist of 17.6 mln units at $0.965/unit
Friday, 13 May 2016 09:00am EDT 

Aveo Pharmaceuticals Inc : Private placement will consist of 17.6 million units, at a price of $0.965 per unit . Aveo pharmaceuticals inc says expects to use proceeds from financing to fund its u.s. Pivotal phase 3 trial of tivozanib .Aveo announces $17 million private placement.  Full Article

SEC seeks to block ex-Aveo CFO's testimony about consulting counsel

The Securities and Exchange Commission is seeking to block the former chief financial officer of Aveo Pharmaceuticals Inc from testifying at his upcoming trial that he relied on lawyers before making statements the regulator claims were misleading.